The global at-home cancer testing market is set to experience significant growth over the next decade, according to a new report by Future Market Insights. The market is projected to surge at a compound annual growth rate (CAGR) of 5% from 2023 to 2033, reaching a value of USD 11.24 billion by 2033. By the end of 2023, the market is anticipated to be worth USD 6.9 billion.
With cancer continuing to be a major public health burden globally, the demand for early detection methods is rising. As of 2020, cancer claimed nearly 10 million lives, accounting for one in six deaths worldwide. The most prevalent types include breast cancer (2.26 million cases), lung cancer (2.21 million cases), and colorectal cancer (1.93 million cases), among others. Furthermore, around 40,000 children are diagnosed with cancer annually, underscoring the critical need for early diagnosis and timely treatment.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-13365
The COVID-19 pandemic has significantly influenced the growth of the at-home cancer testing market. During the pandemic, healthcare systems redirected their focus towards managing the infection, leading to a reduction in on-premise cancer diagnosis and treatment services. This shift prompted individuals to seek alternative ways to monitor their health, resulting in a surge in the adoption of at-home cancer testing kits.
The United States is emerging as a key market for at-home cancer testing services. Due to the pandemic, oncology procedures at institutions like Massachusetts General Hospital saw a substantial decline, with levels reaching only 72% of 2019 figures in late 2020 and 84% in 2021. As the healthcare system gradually recovers, there is a growing emphasis on home-based testing solutions to avoid delays in diagnosis and treatment.
Recent advancements in at-home cancer testing technologies have further fueled market growth. In January 2023, LifeCell introduced the first at-home self-test kit for detecting Human Papillomavirus (HPV), a significant cause of cervical cancer. This innovation is particularly impactful given the high prevalence and mortality rate of cervical cancer among women.
Similarly, researchers at Purdue University are developing a paper-based device to detect cervical cancer, promising quick and convenient results without the need for clinical appointments. This test is expected to be both affordable and accessible, potentially preventing the onset of the disease in many women.
Established market players are also enhancing their oncology research capabilities to introduce advanced testing kits and therapies. In August 2022, Exact Sciences Corp. partnered with the West German Study Group (WSG) to conduct a prospective, multicenter validation study in early breast cancer patients. This collaboration aims to demonstrate the efficacy of Exact Sciences’ tumor-informed ctDNA liquid biopsy test in detecting minimal residual disease (MRD), with data from approximately 3,000 German patients enrolled in ongoing trials.
There are several factors driving the demand for at-home cancer testing:
- Rising Rates of Cancer: As the population ages, there’s a natural increase in cancer diagnoses. At-home tests offer a convenient way for people to monitor their health.
- Early Detection is Key: Catching cancer early is essential for successful treatment. At-home tests can help people identify potential issues before symptoms arise.
- Focus on Preventive Care: There’s a growing emphasis on preventive healthcare, and at-home cancer tests align with this trend by empowering individuals to take a proactive approach to their health.
- Convenience and Ease of Use: At-home tests are often non-invasive and easy to use, removing barriers that might prevent people from getting screened through traditional methods.
- Technological Advancements: The field of diagnostics is constantly evolving, with new at-home tests becoming more accurate and user-friendly.
Overall, the at-home cancer testing market is expected to grow significantly in the coming years due to these factors.
Ask for Customize Research Report: https://www.futuremarketinsights.com/customization-available/rep-gb-13365
Some of the leading manufacturers and suppliers of At-Home Cancer Testing include
- ELITech Group SAS
- Everlywell, Inc.
- Exact Sciences Corp.
- Laboratory Corporation of America Holdings
- Lepu Medical Technology Co., Ltd.
- GY Highland Biotech LLC
- ulti med Products GmbH
- Abingdon Health Quidel Corporation
- Others
Key Segments:
By Cancer Type:
- Colon
- Breast
- Prostate
- Blood
- Bladder
By Sample:
- Blood
- Urine
- Cell
- Stool
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online pharmacies
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Get Complete Full Report: https://www.futuremarketinsights.com/checkout/13365
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube